Microencapsulated 3-piperidinyl-substituted...

Details Microencapsulated 3-piperidinyl-substituted... Microencapsulated 3-piperidinyl-substituted...

2007-07-13

2009-06-16

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Capsules

C424S497000, C514S258100, C514S964000

Reexamination Certificate

active

07547452

ABSTRACT:
Sustained-release microparticle composition. The microparticle composition can be formulated to provide extended release over a period of from about 7 days to about 200 days. The microparticles may be formulated with a biodegradable and biocompatible polymer, and an active agent, such as risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing.

REFERENCES:
patent: 3923288 (1975-12-01), King et al.
patent: 4034965 (1977-07-01), King et al.
patent: 4111402 (1978-09-01), Barbini et al.
patent: 4128641 (1978-12-01), Itil et al.
patent: 4201482 (1980-05-01), Imhauser et al.
patent: 4208136 (1980-06-01), King et al.
patent: 4324870 (1982-04-01), Rim et al.
patent: 4329331 (1982-05-01), Kallick et al.
patent: 4335127 (1982-06-01), Vandenberk et al.
patent: 4337261 (1982-06-01), Shutske et al.
patent: 4342870 (1982-08-01), Kennis et al.
patent: 4352811 (1982-10-01), Strupczewski et al.
patent: 4384975 (1983-05-01), Fong
patent: 4443451 (1984-04-01), Kennis et al.
patent: 4458076 (1984-07-01), Strupczewski
patent: 4485107 (1984-11-01), Kennis et al.
patent: 4489055 (1984-12-01), Couvreur et al.
patent: 4511258 (1985-04-01), Federighi et al.
patent: 4529727 (1985-07-01), Kennis et al.
patent: 4542025 (1985-09-01), Tice et al.
patent: 4585482 (1986-04-01), Tice et al.
patent: 4614440 (1986-09-01), King
patent: 4616937 (1986-10-01), King
patent: 4643584 (1987-02-01), Allocca
patent: 4665075 (1987-05-01), Vandenberk et al.
patent: 4675189 (1987-06-01), Kent et al.
patent: 4677191 (1987-06-01), Tanaka
patent: 4683288 (1987-07-01), Tanaka et al.
patent: 4689330 (1987-08-01), Janssens et al.
patent: 4696258 (1987-09-01), Magrath et al.
patent: 4708861 (1987-11-01), Popescu et al.
patent: 4731205 (1988-03-01), McNulty
patent: 4737500 (1988-04-01), Sorg
patent: 4753535 (1988-06-01), King et al.
patent: 4765204 (1988-08-01), Buchholz et al.
patent: 4793713 (1988-12-01), King
patent: 4798786 (1989-01-01), Tice et al.
patent: 4804663 (1989-02-01), Kennis et al.
patent: 4808007 (1989-02-01), King
patent: 4835139 (1989-05-01), Tice et al.
patent: 4883666 (1989-11-01), Sabel et al.
patent: 4897268 (1990-01-01), Tice et al.
patent: 4936689 (1990-06-01), Federighi et al.
patent: 4994281 (1991-02-01), Muranishi et al.
patent: 5008114 (1991-04-01), Lovrecich
patent: 5075109 (1991-12-01), Tice et al.
patent: 5102872 (1992-04-01), Singh et al.
patent: 5143661 (1992-09-01), Lawter et al.
patent: 5158952 (1992-10-01), Janssen et al.
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5453425 (1995-09-01), Francois et al.
patent: 5503851 (1996-04-01), Mank et al.
patent: 5585460 (1996-12-01), Yamada et al.
patent: 5650173 (1997-07-01), Ramstack et al.
patent: 5688801 (1997-11-01), Mesens
patent: 5759563 (1998-06-01), Yewey et al.
patent: 5770231 (1998-06-01), Mesens
patent: 5792477 (1998-08-01), Rickey et al.
patent: 5851451 (1998-12-01), Takechi et al.
patent: 5919408 (1999-07-01), Muller et al.
patent: 5965168 (1999-10-01), Mesens
patent: 6045830 (2000-04-01), Igari et al.
patent: 6080429 (2000-06-01), Cleland et al.
patent: 6110503 (2000-08-01), Rickey
patent: 6110921 (2000-08-01), Mesens
patent: 6224794 (2001-05-01), Amsden et al.
patent: 6368632 (2002-04-01), Mesens
patent: 2008/0063721 (2008-03-01), Mesens et al.
patent: 0 052 510 (1982-05-01), None
patent: 0 071 454 (1983-02-01), None
patent: 0 129 619 (1985-01-01), None
patent: 0 195 450 (1986-09-01), None
patent: 0 196 132 (1986-10-01), None
patent: 0 248 531 (1987-12-01), None
patent: 0266 119 (1988-05-01), None
patent: 0368 388 (1990-05-01), None
patent: 0 486 959 (1992-05-01), None
patent: 0 452 111 (1998-07-01), None
patent: 0 605 933 (1998-10-01), None
patent: 0 724 433 (1998-12-01), None
patent: 0 709 085 (2001-01-01), None
patent: 0 761 213 (2002-10-01), None
patent: 1 214 058 (2003-07-01), None
patent: 1 033 973 (2003-09-01), None
patent: 0 975 334 (2003-10-01), None
patent: 1 345 979 (2004-07-01), None
patent: 1 212 730 (1970-11-01), None
patent: 1 351 811 (1974-05-01), None
patent: 2 015 360 (1979-09-01), None
patent: 2 120 113 (1983-11-01), None
patent: 2 246 573 (1992-02-01), None
patent: 2 265 311 (1993-09-01), None
patent: WO-88/01165 (1988-02-01), None
patent: WO-90/13361 (1990-11-01), None
patent: WO-91/02527 (1991-03-01), None
patent: WO-91/13595 (1991-09-01), None
patent: WO-91/17772 (1991-11-01), None
patent: WO-94/10982 (1994-05-01), None
patent: WO-94/25460 (1994-11-01), None
patent: WO-95/13799 (1995-05-01), None
Abstract of WO 94/10982, Kino et al., “Sustained-release Microspheres Requiring No Surgical Implant—Contains Hydriophobic Antipsychotic Encapsulated in Biodegradable Polymer, Allowing Prolonged Therapeutic Effect by Infrequent Administration,” (July 1994).
Alonso et al., Pharmaceutical Research, 10(7):945-953 (1993).
Baker, J.R., “Motionless Mixers Stir Up New Uses,” Chemical Engineering Progress, 32-38 (Jun. 1991).
Bodmeier, R. et al., Solvent selection in the preparation of poly(DL-lactide) microspheres prepared by the solvent evaporation method, International Journal of Pharmaceutica, 43:179-186 (1988).
Borison, R.L. et al., Clinical Overview of Risperidone, “in” Meltzer, H., Y., ed., Novel Antipsychotic Drugs, Raven Press, Ltd., N.Y.: 233-239 (1992).
Chang, R. et al., “Dissolution Characteristics of Polycaprolactone-Polylactide Microspheres of Chlorpromazine,” Drug Development and Industrial Pharmacy, 12(14):2355-2380 (1986).
Chemineer, “Kenics Static Mixers,” Bulletin 800:1-11 (1986).
Chouinard, G. et al., “A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperiodol in the Treatment of Chronic Schizophrenic Patients,” Journal of Clinical Psychopharmacology, 13(1):25-40 (1993).
Fong, J. W. et al., Enhancing Drug Release from Polylactide Microspheres by Using Base in the Microencapsulation Process, American Chemical Society, Chapter 16, 214-230 (1987).
Gangrade and Price, J. Microencapsulation, 8(2):185-202 (1991).
Glazer, W.M. et al., “Depot Neuroleptic Therapy: An Underutilized Treatment Option,” J. Clin. Psychiatry, 53(12):426-433 (Dec. 1992).
Heinrich, K. et al., “Experimental Comparison of the Efficacy and Compatibility of Risperidone and Clozapine in Acute Schizophrenia,” in: Kane, J.M. (ed), Risperidone: Major Progress in Antipsychotic Treatment.Oxford Clinical Communications, Oxford, 37-39 (1991).
Herrling, P.L., Mechanism of Action of Atypical Antipsychotics, Pharmacopsychiat., 24:48-49 (1991).
Janssen, P.A.J. et al., Is it Possible to Predict the Clinical Effects of Neuroleptic Drugs (Major Tranquilizers) from Animal Data?,Arzneimit. Forsch. (Drug Res.) 10:1196-1206 (1965).
Janssen, P.A.J. et al., “Pharmacology of Risperidone (R 64 766), a New Antipsychotic with Serotonin—S2and Dopamine-D2Antagonistic Properties,” The Journal of Pharmacology and Experimental Therapeutics, 44(2):685-693 (1988).
Janssen and Niemegeers,“Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4-phenyl-piperidino)-butyrophenone,”Arzneim.-Forsch. (Drug Res.), 12:765-767 (1959).
Koch Engineering Co., Inc., Static Mixing Technology advertisement, pp. 1-15.
Koch Engineering Company Inc., All Mixing Problems Are Not Alike, 1 page, Product Brochure (No date available).
Koflo Corporation, “Static In-Line Mixers,” 4 pages, Product Brochure (no date available).
Komax Systems, Inc., “Triple Action Static Mixers,” 2 pages, Product Brochure (No date available).
Leysen, J.E. et al., “Biochemial Profile of Risperidone, a New Antipsychotic,” The Journal of Pharmacology and Experimental Therapeutics, 247(2):661-670 (1988).
Leyson, J.E. et al., “In vitro receptor binding and neurotransmitter uptake inhibition profile of R 64 766, R 76 477, R 78 543 and 78 544,” Janssen Research Foundation, Beerse, Belgium, M 79120, Preclinical Research Report R 64 766/28, 11 pages (Jan. 1991).
Li et al., J. Controlled Release, 37:199-214 (1995).
Maulding, et al., &#

Affiliated with

Also associated with

Rating

Microencapsulated 3-piperidinyl-substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Microencapsulated 3-piperidinyl-substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microencapsulated 3-piperidinyl-substituted... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4103379